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Abstract
Background: Prolonged acute hospital stays are a problem for older people and for health services. Failure to
effectively manage the psychological and social aspects of illness is an important cause of prolonged hospital stay.
Proactive Psychological Medicine (PPM) is a new way of providing psychiatry services to medical wards which is
proactive, focussed, intensive and integrated with medical care. The primary aim of PPM is to reduce the time older
people spend in hospital because of unmanaged psychological and social problems. The HOME Study will test the
effectiveness and cost-effectiveness of PPM.
Methods/design: The study is a two-arm, parallel-group, randomised, controlled superiority trial with linked health
economic analysis and an embedded process evaluation. The target population is people aged 65 years and older
admitted to acute hospitals. Participants will be randomly allocated to either usual care plus PPM or usual care
alone. The primary outcome is the number of days spent as an inpatient in a general hospital in the month
following randomisation. Secondary outcomes include quality of life, cognitive function, independent functioning,
symptoms of anxiety and depression, and experience of hospital stay. The cost-effectiveness of usual care plus PPM
compared with usual care alone will be assessed using quality-adjusted life-years as an outcome as well as costs
from the NHS perspective.
Discussion: This update to the published trial protocol gives a detailed plan of the statistical and economic analysis
of The HOME Study.
Trial registration: ISRCTN registry, ISRCTN86120296. Registered on 3 January 2018.
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Background
In the United Kingdom, National Health Service (NHS)
acute hospitals have more than 2 million unplanned ad-
missions of people aged 65 years and older annually.
The greater length of stay of older patients means that
these admissions account for most (70%) of the available
emergency bed days [1]. Excessive time in hospital is
bad for patients: it leads to hospital-acquired illnesses,
demoralisation and loss of independence after discharge
[2]. It is also bad for hospitals because it reduces the
availability of beds for other people and increases costs.
Strategies to reduce length of stay as well as to reduce
admissions are considered to be essential to addressing
this problem [3]. A recent review found that, whilst
many of the initiatives which aimed to achieve this
showed promise, none were of proven effectiveness [4].
The reasons for prolonged hospital stays include not
only the complexity of older patients’ medical problems
but also inadequately managed psychological and social
problems. The psychological problems include psychi-
atric illnesses such as delirium, dementia, and depres-
sion, as well as minor cognitive impairment or anxiety,
all of which may slow patients’ discharge from hospital
[5, 6]. The social problems include delays in organising
post-discharge care arrangements, family members’ ex-
pectations or concerns about where the patient will go
when leaving hospital, and miscommunications and con-
flicts about discharge planning within the clinical team.
Failure to effectively manage these problems is well doc-
umented [7].
We have developed a new way of delivering psychiatry
in acute hospitals called Proactive Psychological Medi-
cine (PPM) that aims to address these problems and
therefore reduce time spent in hospital. PPM is pro-
active, takes a broad biopsychosocial approach, provides
comprehensive consultant assessment and daily follow-
up, and is integrated with the patient’s medical care.
The HOME Study
The HOME Study is a two-arm, parallel-group, rando-
mised, controlled superiority trial with a linked health eco-
nomic analysis and an embedded process evaluation. The
trial will evaluate the effectiveness and cost-effectiveness
of adding PPM to usual care compared with usual care
alone. The HOME Study protocol was published previ-
ously [8]. This article describes the trial’s statistical and
economic analysis plan. This plan has been reviewed and
approved by the trial steering committee (TSC) and the
data monitoring committee (DMC).
Research objectives
Primary outcome
The main aim of the study is to determine whether add-
ing PPM to usual care affects the time (in days) spent as
an acute hospital inpatient in the 30 days post random-
isation. Any time spent as an inpatient on a particular
calendar date will be counted as a day in hospital.
Secondary outcomes
The additional aims of the study are to investigate
whether adding PPM to usual care affects the following:
1. Cognitive function, measured by the Montreal
Cognitive Assessment–Telephone version (MOCA-
T) at 1 and 3 months post randomisation [9]
2. Independent functioning, measured by the Barthel
Index of Activities of Daily Living at 1 and 3
months post randomisation [10]
3. Health-related quality of life, measured by the
European Quality of Life–5 Dimensions–5 Levels
(EQ-5D-5L) questionnaire at 1 and 3 months post
randomisation [11]
4. Symptoms of anxiety and depression, each
measured by the relevant two items of the Patient
Health Questionnaire-4 (PHQ-4) at 1 and 3 months
post randomisation [12]
5. Overall quality of life, measured by a trial-specific
item (0–10 scale) at 1 and 3 months post
randomisation
6. Patient’s experience of hospital stay, measured by a
trial-specific item (0–10 scale) at 1 month post
randomisation
7. Patient’s view of the length of their hospital stay,
measured by a trial-specific item at 1 month post
randomisation
8. Discharge destination
9. Secondary healthcare use in the 1 year posts
randomisation (including total length of index
admission, number of readmissions, and number of
days in hospital)
10. Death in the 1 year post randomisation
Health economic aims
A further aim is to assess the cost-effectiveness of add-
ing PPM to usual care compared with usual care alone
from the NHS perspective. This will be done by measur-
ing the following:
 Quality-adjusted life-years (QALYs), estimated using
the EQ-5D-5L measure
 The cost of providing PPM
 The cost of secondary healthcare use
Outcomes will be measured at the time points detailed
in Table 1. The table also includes information about
how data will be collected.
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Methods
Trial design
The study is a pragmatic, multicentre, two-arm,
parallel-group, randomised, controlled superiority trial
with a linked health economic analysis and an
embedded process evaluation. The experimental inter-
vention is PPM in addition to usual care delivered by
trained clinicians working as members of the medical
teams. The comparator is usual care alone. Further
details about the trial design can be found in the trial
protocol [8].
Trial treatments
The trial compares two service models: usual care and
usual care supplemented with PPM, which has four
main components:
1. Early proactive assessment of newly admitted
patients using a biopsychosocial approach to
identify all the patient’s problems, including
psychiatric illness
2. The creation of a systematic management plan to
address those problems that pose potential barriers
to prompt discharge from hospital
3. Active implementation of this management plan
with daily progress reviews
4. Integrated working with ward teams (doctors,
nurses, allied health professionals and social care
professionals) and out-of-hospital services to ensure
that the management plan is implemented
PPM will be delivered at each trial site by a specially
trained consultant in psychological medicine/liaison
psychiatry and an assisting clinician, working as
additional members of the patient’s medical team. Fur-
ther details can be found in the trial protocol [8].
The comparator treatment is usual care. Usual medical
care includes the option for the patient’s medical team
to request a consultation from the hospital’s usual
liaison psychiatry team.
Randomisation and blinding
Participants will be allocated to trial arms by stratified
randomisation. A database software algorithm for allo-
cating participants was designed by the senior trial stat-
istician. The algorithm allocates participants to usual
care plus PPM or to usual care alone in a 1:1 ratio, with
stratification done by putative prognostic variables: hos-
pital, sex, and age (65–74, 75–84, ≥85 years). The algo-
rithm is based on the ‘ralloc’ command in Stata software
(StataCorp, College Station, TX, USA) and uses random
permuted blocks of variable size. The required random
seed was selected by the Oxford Clinical Trials Research
Unit (OCTRU), which will implement the randomisation
system. The participant’s details will be entered into a
database via a secure website by the researchers who re-
cruit participants. Their treatment allocation will be
automatically generated once the participant’s baseline
data have been entered. Neither study researchers nor
participants will therefore be able to predict treatment
allocation. A study researcher will inform the patients of
Table 1 Time points and methods of data collection for HOME Study outcomes
Outcome 1 Month (30 days) post
randomisation
3 Months (90 days)
post randomisation
1 Year post
randomisation
Method of data
collection
No. of days in hospital in the month (30 days) post
randomisation
✓ Routine data/medical
records
Cognitive function (MOCA-T) ✓ ✓ Patient
Independent functioning (Barthel Index of
Activities of Daily Living)
✓ ✓ Patient/proxy
Health-related quality of life (EQ-5D-5L) ✓ ✓ Patient/proxy
Anxiety and depression symptoms (PHQ-4) ✓ ✓ Patient/proxy
Overall quality of life (study-specific item) ✓ ✓ Patient/proxy
Experience of hospital stay (study-specific item) ✓ Patient/proxy
View on length of hospital stay (study-specific
item)
✓ Patient/proxy
Discharge destination ✓ ✓ ✓ Routine data/medical
records
Secondary healthcare use in the 1 year post
randomisation
✓ Routine data/medical
records
Death ✓ ✓ ✓ Routine data/medical
records
Abbreviations: EQ-5D-5L European Quality of Life-5 Dimensions-5 Levels, MOCA-T Montreal Cognitive Assessment–Telephone version, PHQ-4 Patient
Health Questionnaire-4
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their allocation and will inform PPM teams about partic-
ipants who have been allocated to usual care plus PPM.
The staff who collect outcome data and the study stat-
isticians will be blinded to participants’ allocated inter-
ventions. Study statisticians will carry out analyses with
trial arms described only as ‘A’ and ‘B’. HOME Study re-
searchers who recruit participants will carry out the ran-
domisation procedure described above and therefore will
not be blinded to allocation, nor will it be possible to
blind participants and their clinicians, owing to the na-
ture of the study interventions.
Full details of randomisation and blinding are stored
on a University of Oxford–based server with confidential
access restricted to the OCTRU statistics team. Trial
statisticians do not have access to this, because they are
blind to treatment allocation. Monitoring of the ran-
domisation system is also being undertaken by the
OCTRU statistics team.
Sample size
A total of 3588 participants are required to detect a re-
duction of 1 day (from 9 to 8 days; standard deviation, 9)
in the mean number of days spent in hospital with 90%
power at the 5% significance level, using a two-tailed
weighted t test with weights as specified to be used in
the primary analysis and allowing for 5% loss to follow-
up. The value of the expected standard deviation was
obtained from pilot data.
A series of measures will be taken aimed at achieving
the target sample size:
 Researchers will be embedded in clinical teams at
each study centre.
 Screening of patients will be used to obtain a
representative sample of the relevant population and
to give all potentially eligible patients the
opportunity to participate.
 Researchers will be trained in how to explain the
study to patients who are unwell and to their carers.
 Multiple wards will be used for recruitment at each
study centre.
 The trial management group (TMG) will monitor
recruitment weekly to ensure identification of
problems and implement solutions.
Outcome data collection
Data describing the participant’s hospital stay, discharge
destination, subsequent hospital admissions, secondary
healthcare use and mortality will be obtained from na-
tional datasets of routinely collected clinical data and
from local hospital records and datasets. At 1 month (30
days) and 3months (90 days) post randomisation, a
member of the research team will contact the participant
(or an appropriate proxy) to administer the study
questionnaires, either by telephone or face to face. All
members of the research team will be trained in the
standard operating procedures for the tasks they are al-
located, and their competency will be assessed by the
central trial team. The majority of the secondary out-
come data will be collected by telephone by the central
trial outcome team.
The measures that will be taken to minimise missing
data include the following:
 For the primary outcome, we will use routinely
collected NHS clinical data.
 For the secondary outcomes we will:
Obtain full contact details from participants
as well as a back-up ‘best contact’ address (i.e.,
contact details of a friend/relative nominated by
the participant)
Record participants’ discharge destination
from hospital
Collect data from proxies when participants
are unable to give reliable data
Use reminder telephone calls and letters
Check with the patient’s general practitioner
regarding whether they are alive and/or have
moved their address before collecting outcomes
Statistical interim analysis, data review and stopping
guidelines
The HOME Study has a DMC, which will monitor trial
data and make recommendations to the TSC on whether
there are any ethical or safety reasons why the study
should not continue. DMC members will act independ-
ently of the TSC, TMG and funder. The DMC will
monitor data at two interim assessment time points (i.e.,
analysis will be done at three time points in total, includ-
ing the final assessment) and will receive a report from
the trial statisticians, who will attend only by invitation.
The assessment times are defined as the time point at
which 1200 (approximately one-third), 2400 (approxi-
mately two-thirds) and 3588 patients (the final sample
size) have been recruited to the trial and have been
followed up for30 days.
In open sessions, the DMC will review summaries of
participants’ baseline characteristics (both trial arms
combined), including the following:
 Hospital where the participant was recruited
(randomisation stratifier)
 Sex (randomisation stratifier)
 Age (randomisation stratifier)
 Number of participants in the strata (i.e., the 24-
category combination of age [3 groups], sex [2
groups] and hospital [up to 4 groups])
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 Cognitive function (MOCA-T; a secondary
outcome)
 Independent functioning (Barthel Index of Activities
of Daily Living; a secondary outcome)
 Health-related quality of life (EQ-5D-5L; a
secondary outcome)
 Depression and anxiety symptoms (PHQ-4; a
secondary outcome)
 Overall quality of life (study-specific item; a
secondary outcome)
The DMC will also monitor the data completeness
(proportion of complete data) of secondary outcome
data at the 1- and 3-monthfollow-up time points. Partic-
ipants will be placed into one of three categories: (1)
complete data obtained; (2) partial data obtained; or (3)
no data obtained, with reasons listed for those in this
final category. Data completeness will not be assessed by
trial arm in open sessions.
In closed sessions, the DMC will monitor semi-
blinded data, which is to say that the trial arms will be
labelled as ‘A’ and ‘B’. In these sessions, the DMC will
review the number of participants randomised to each
stratum, baseline characteristics, and data completeness,
by trial arm. The DMC will also monitor the occurrence
of serious adverse events (SAEs) and (if unblinded) sus-
pected unexpected serious adverse reactions (i.e., SAEs
that are likely to be due to the implementation of PPM).
The DMC will focus on the number of participant
deaths that occur within 30 days of study enrolment. In
these sessions, the number of participants randomised to
each stratum, baseline data, and data completeness will
be monitored by trial arm.
Interim analyses of the primary outcome data will not
be undertaken, because these require data that will not
be available during the relatively short recruitment
period. There are therefore no statistical stopping rules
for benefit in this study; the DMC will recommend stop-
ping only on safety grounds. The trial statistician will
provide tabular summaries of all-cause mortality by
semi-blinded trial arm (A/B) and by the randomisation
stratifiers. The DMC statistician member will use
Fisher’s exact test to assess the null hypothesis that the
all-cause mortality rates in the two trial arms are the
same. To address multiplicity concerns about repeatedly
testing at every interim assessment time point, the
O’Brien-Fleming sequential stopping method will be
implemented. This requires application of Fisher’s exact
test with P values for statistical significance set at
0.0005, 0.014 and 0.045 at the first, second and final as-
sessment time points, respectively [13]. The test at the
final assessment will not be used to stop the trial; it will
be used only to assess the statistical significance of the
difference seen at the final analysis. Tests will be two-
sided. If a statistically significant difference between trial
arms in all-cause mortality is detected, a clinical sub-
group of the DMC will be unblinded to allocation status
and will determine, through case note review, whether
PPM could have led to any of the excess deaths.
Timing of final analysis
The final analysis will be completed once all data have
been collected and the database has been locked. All
outcomes and time points will be assessed at the same
time.
Blinded analysis
All statistical analyses will be carried out with trial arms
described only as ‘A’ and ‘B’.
Statistical properties
Statistical significance and multiple testing
The study aims to determine whether adding PPM to
usual care reduces the time (days) spent by patients in
acute hospitals in the 1 month post randomisation. Con-
sequently, there is only one primary outcome and no
multiple testing in the main effectiveness analysis. Hy-
pothesis tests relating to the secondary outcomes are
considered to be exploratory. Therefore, the significance
level used will be 0.05, and 95% confidence intervals will
be reported. The one exception to this will be the ana-
lysis of treatment effect on deaths (secondary outcome
10). This outcome will be the subject of interim analyses
conducted by the DMC, for which the O’Brien-Fleming
sequential stopping rule is being used [13]. The planned
test level at the final assessment time point is 0.045. The
DMC will make multiple tests of the null hypothesis that
there is no difference in deaths between the trial arms.
Adjustment has been made for the inflation of the type I
error which is a consequence of these multiple tests.
Definition of analysis populations
The trial is designed primarily to assess effectiveness
(i.e., the effect of treatment in everyday conditions) [14].
It will also assess efficacy for the primary outcome. All
analyses of effectiveness will follow the intention-to-treat
(ITT) principle, which states, ‘The effect of a treatment
policy can be best assessed by evaluating on the basis of
the intention to treat a subject (i.e. the planned treat-
ment regimen) rather than the actual treatment given’
[15]. Effectiveness analysis populations will be defined as
the ITT population, and all randomised participants will
be included in their randomised groups. For these ana-
lyses, participants will be analysed according to the
group to which they were randomised and not according
to the intervention they actually received.
An efficacy analysis of the primary outcome will be
carried out using per-protocol analysis and will use
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covariate adjustment (covariates of age, centre, and sex)
with the aim of minimising selection bias. Using the def-
inition of treatment receipt that will be described later,
this analysis will exclude those participants who are re-
corded as not having received treatment; that is, out-
comes will be compared between randomised treatment
groups for a subset of the ITT population. This subset
will include those PPM arm participants who receive the
intervention and all usual care arm participants. This
analysis will unblind the trial statisticians and will there-
fore be carried out once all other analyses have been
completed.
Trial population and descriptive analyses
Eligibility
Participants will be recruited from the acute wards (not
emergency departments) of Oxford University Hospitals
NHS Foundation Trust, Royal Devon and Exeter NHS
Foundation Trust, and Cambridge University Hospitals
NHS Foundation Trust. To be included in the trial, pa-
tients must
 Be aged 65 years or older
 Be an inpatient in an acute ward where trial
recruitment is taking place
 Have been admitted non-electively (i.e., their hos-
pital admission was unplanned)
 Be expected by their clinical team to remain an
inpatient for at least 2 days from the time of trial
enrolment
 Be able to give informed consent or, if unable to
give consent, a consultee advises that trial
participation is appropriate
Patients will be excluded if at the time of enrolment
 They are moribund, which is defined for this trial as
the clinicians caring for the patient estimating that
they are likely to die before discharge from hospital
 Their participation in the trial is judged to be
clinically or practically inappropriate (e.g., the
patient is not from the local area served by the
hospital)
 They have already been enrolled in the trial
 They have already been referred to the usual care
liaison psychiatry team
 They have already been a general hospital inpatient
continuously for 1 week
 They do not read or speak English
Representativeness of study sample and patient throughput
The flow of participants through the trial will be sum-
marised as a Consolidated Standards of Reporting Trials
(CONSORT) diagram, as shown in Fig. 1.
Withdrawal from treatment and/or follow-up
It is anticipated that some participants may withdraw
from data collection. This may involve withdrawal from
providing questionnaire data or withdrawal of consent
for the collection of any data (both questionnaire data
and data collection from healthcare records and relevant
databases). Patients (or their representatives on their be-
half) may decide, during their participation in the study,
to refuse relevant interventions; these refusals will be
noted but will not be considered withdrawals from the
study. Withdrawals and loss to follow-up, together with
reasons, will be reported by trial arm. Any deaths (and
their causes) will be reported separately.
Baseline comparability of randomised groups
The following data will be collected at baseline:
 Hospital where the participant is recruited
 Age
 Sex
 Ethnicity (white British; white Irish; any other white
ethnic background; white and black Caribbean;
white and black African; white and Asian; any other
mixed background; Indian; Pakistani; Bangladeshi;
any other Asian background; Caribbean; African;
any other black background; Chinese; any other
ethnic group; not stated)
 Relationship status (spouse/partner; no spouse/
partner)
 Usual place of residence (private residence; care
home or nursing home; other)
 Whether admitted from usual place of residence
(yes; no)
 If not admitted from usual residence, where the
participant was admitted from (other hospital;
private residence, not patient’s own; care home/
nursing home, not patient’s normal home; other)
 Index of Multiple Deprivation based on home
postcode
 Rural/urban classification of the participant’s home
based on postcode (urban major conurbation; urban
minor conurbation; urban city and town; urban city
and town in a sparse setting; rural town and fringe;
rural village; rural hamlets and isolated dwellings;
rural town and fringe in a sparse setting; rural
village in a sparse setting; rural hamlets and isolated
dwellings in a sparse setting)
 Whether the participant lives alone (yes; no)
 Employment status (working; retired; not working
due to health; not working for another reason)
 Reason for hospital admission (recorded as free text
and to be summarised using a categorisation that
will be formed)
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 Diagnoses (medical and psychiatric) recorded on
admission
 Medication prescribed
 Days in hospital prior to enrolment, meaning days
spent in hospital between admission and
randomisation, not counting the day of
randomisation itself (e.g., if someone was admitted
at some time the day before being randomised, this
would count as 1 day)
 Cognitive function (MOCA-T)
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of the flow of participants through the trial
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 Independent functioning (Barthel Index of Activities
of Daily Living)
 Health-related quality of life (EQ-5D-5L)
 Depression and anxiety (PHQ-4)
 Overall quality of life (study-specific item)
 Secondary healthcare use (including number of
admissions to hospital) in the year prior to
randomisation
These baseline characteristics will be reported by trial
arm and for both arms combined. Numbers (with per-
centages) for categorical variables and means (and stand-
ard deviations) or medians (with lower and upper
quartiles) for continuous variables will be presented.
There will be no tests of statistical significance or confi-
dence intervals for differences between randomised
groups on any baseline variable.
Description of receipt of intervention
Receipt of intervention is defined as having occurred
when a PPM clinician has reviewed the participant’s case
and completed an assessment and an action plan for
them. The completion of the minimum requirement will
be summarised within the PPM trial arm using absolute
and relative frequencies. Other elements of the interven-
tions given will also be described. The PPM consultation
will not be available to any participant in the usual care
trial arm, so no participant in that arm will be excluded
from the per-protocol analysis.
Analysis
Outcome definitions
Primary outcome Time (days) spent by participants in
acute hospitals in the 30 days post randomisation. A day
in hospital is defined as a patient spending any time in
hospital on a particular date. If this participant remains
in hospital for even a short period of time after midnight
on the next calendar date, this is defined as an additional
day spent in hospital.
Secondary outcomes
1. Cognitive function measured using the MOCA-T at
1 and 3 months post randomisation [9]; we will use
standard scoring [16].
2. Independent functioning measured using the
Barthel Index of Activities of Daily Living at 1 and
3 months post randomisation [10]; we will use
standard scoring [17].
3. Health-related quality of life measured using the
EQ-5D-5L at 1 and 3 months post randomisation
[11]. Responses to the five items of the EQ-5D-5L
will be transformed into a health-related quality of
life score using two methods: (1) van Hout et al.’s
crosswalk algorithm [18] and UK EQ-5D-3L value
set [19] and (2) the UK EQ-5D-5L value set [20].
The former of these represents the National Insti-
tute for Health and Care Excellence’s preferred
method [21].
4. Symptoms of anxiety and depression measured by
the PHQ-4 at 1 and 3 months post randomisation;
we will use standard scoring [12].
5. Overall quality of life measured using a study-
specific item at 1 and 3 months post randomisation.
This item is measured on an interval scale where
scores range between 0 and 10. Higher scores indi-
cate better quality of life.
6. Participants’ experience of hospital stay measured
using a study-specific item at 1 month post ran-
domisation. This item is worded: ‘Thinking about
your recent hospital stay, on a scale of 0–10, where
0 is terrible and 10 is excellent, how would you rate
the care you received in hospital’?
7. Participants’ views on the length of their hospital
stay as measured using a study-specific item at 1
month post randomisation. The item is worded
thus: ‘Thinking about your recent hospital stay,
what do you think about your stay in hospital –
was it too short, about right, or too long’?
8. Discharge destination. This outcome is measured at
1 month, 3 months and 1 year post randomisation.
Discharge destination is coded as follows: A (private
residence, patient’s own); B (private residence, not
patient’s own); C (care home/nursing home,
patient’s normal home); D (care home/nursing
home, temporary placement); E (care home/nursing
home, acute hospital bed); F (community hospital);
G (hospice); H (psychiatric hospital); or I (other).
The outcome will be coded as a dichotomous
variable whose levels are private residence (levels A
and B above) and not private residence (levels C, D,
E, F, G, H and I above).
9. Secondary healthcare use in the 1 year post
randomisation, including total length (days) of
index admission post randomisation, number of
readmissions, and number of days in hospital.
10. Deaths in the 1 year post randomisation.
Statistical analysis methods
All outcomes will be described in tabular format by trial
arm and time point. Discharge destination will be sum-
marised by its nine levels rather than by the dichotomi-
sation used for inferential analysis. Means and standard
deviations as well as medians and interquartile ranges
will be reported for all continuous outcomes (including
time-to-event outcomes). Categorical outcomes will be
described using absolute and relative frequencies.
Magill et al. Trials          (2020) 21:373 Page 8 of 14
The treatment effect for the primary outcome (number
of days spent in hospital in the 30 days post randomisa-
tion) will be estimated using a linear regression model.
The model will include (1) centre (Cambridge, Exeter or
Oxford) by treatment interaction terms, (2) stratification
factors (hospital, sex and age, which will be treated as
continuous in the analysis model) as fixed effects, and
(3) wards as fixed or random effects (the final choice be-
ing dependent on the number of wards included). The
effect of treatment on the primary outcome will be a
weighted mean of the three centre-specific treatment ef-
fects, with weights proportional to the number of people
randomised at each centre. As a check on the robustness
of results to normality assumptions, non-parametric
bootstrap methodology (bias corrected and accelerated,
2000 replications, with allowance for stratification) will
be used to construct the confidence interval. The differ-
ence between the means together with a 95% confidence
interval will be reported.
Secondary outcome numbers 1, 2, 3, 4 and 5 (MOCA-
T, Barthel, EQ-5D, anxiety and depression subscales of
PHQ-4, study-specific measure of overall quality of life)
are recorded at baseline, 1 month post randomisation
and 3 months post randomisation. Treatment effects will
be estimated using analysis of covariance; that is, post-
randomisation measures will be included in the outcome
vector, and baseline measures will be treated as covari-
ates. Data will be arranged in wide format (one partici-
pant per row), and treatment effects at 1 and 3months
post randomisation will be estimated using separate
models. This is to allow the use of multiple imputation
(MI) (see the next section on missing data). Models will
include the fixed effects that were described in the
model for the primary outcome together with a fixed ef-
fect for outcome measured at baseline. The estimated ef-
fect of treatment will be a weighted mean of the three
centre-specific treatment effects at each of the post-
randomisation time points. As a check on the robustness
of results to normality assumptions, confidence intervals
will be constructed from bootstrap samples that will be
drawn from each of the multiply imputed datasets (2000
replications, with allowance for stratification) [22]. The
limits of the 95% confidence interval will be calculated
using the 2.5 and 97.5 percentiles of treatment effect es-
timates across all bootstrap samples and across all multi-
ply imputed datasets.
Experience of hospital stay (secondary outcome num-
ber 6) is continuous and measured at 1 month post ran-
domisation. Note that this outcome is not measured at
baseline. Models for this outcome will use linear regres-
sion and will include the same fixed effects as the model
for the primary outcome. This outcome is patient-
reported with an expectation that there will be a consid-
erable amount of missing data (partly due to participants
dying). MI will be used to address this (see the next sec-
tion on missing data). As a check on the robustness of
results to normality assumptions, confidence intervals
will be constructed from bootstrap samples that will be
drawn from each of the multiply imputed datasets (2000
replications, with allowance for stratification) [22].
Secondary outcome number 7 (patient’s view on
length of hospital stay) will be modelled using ordered
logistic regression, provided that there is no evidence
that the proportional odds assumption does not hold. If
the assumption appears broken, the outcome will be
modelled using multinomial logistic regression. This
outcome is patient-reported with an expectation that
there will be a considerable amount of missing data
(partly due to participants dying). MI will be used to ad-
dress this (see the next section on missing data). Second-
ary outcome number 8 (discharge destination) will be
modelled using logistic regression. Covariates will be the
same as those included in the model for the primary
outcome. Analysis will be conditional on the participant
being admitted from a private residence and not being
dead when leaving; that is, the model will be fitted to a
subset of the sample based on this information. The ef-
fect of treatment offer on the outcome will be calculated
in the same manner as for the primary outcome (i.e., as
a weighted mean of the three centre-specific treatment
effects).
Secondary outcome number 9 (secondary healthcare
use in the 1 year post randomisation) will be modelled
using a number of approaches. Total length (days) of
index admission post randomisation will be handled as a
time-to-event outcome. The Cox proportional hazards
model, with censoring for deaths, will be fitted in order
to estimate the effect of treatment. Number of readmis-
sions will be treated as count data, and therefore the
treatment effect will be estimated using a Poisson model
with robust standard errors to allow for likely overdis-
persion and non-independent events. Total time (days)
in hospital will be handled as a continuous outcome,
and the effect of treatment will be estimated using a
model similar to that used for the primary outcome.
Confidence intervals for this model will be estimated by
bootstrapping due to the fact that these outcomes are
expected to be skewed and truncated. For all three of
these models, covariates will be the same as those in-
cluded in the model for the primary outcome. The effect
of treatment offer on the outcome will be calculated in
the same manner as for the primary outcome (i.e., as a
weighted mean of the three centre-specific treatment
effects).
Secondary outcome number 10 (deaths) will be mod-
elled using survival analysis. Kaplan-Meier curves will be
used to plot survival over time by trial arm. The Cox
proportional hazards model will be used to estimate the
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effect of treatment on outcome. Covariates will be the
same as those included in the model for the primary
outcome. The effect of treatment offer on the outcome
will be calculated in the same manner as for the primary
outcome (i.e., as a weighted mean of the three centre-
specific treatment effects).
Missing data including deaths
In the main analysis of the primary outcome, a patient
who dies on a particular day has the same outcome as a
patient who leaves hospital on that day; hence, this can
be interpreted as a hospital-centred analysis. Two sup-
plementary analyses of this outcome will be used to esti-
mate the treatment effect, and these will take more
participant-centred interpretations of death.
For the first supplementary analysis, a participant’s
outcome will be constructed as the time (days) he/she
spent in hospital in the 30 days post randomisation as a
proportion of the time (days) that the participant was
alive during those 30 days. For example, if a participant
died at the end of spending 10 continuous days in hos-
pital, the outcome would count as 1. If another partici-
pant spent 10 days in hospital and then died after a
further 10 days, his/her outcome would be 0.5. The
model for this analysis will include the same fixed effects
described in the main model for the primary outcome.
Outcomes will be weighted by how long participants
were alive in the 30 days post randomisation. As a check
on the robustness of results to normality assumptions,
non-parametric bootstrap methodology (bias corrected
and accelerated, 2000 replications, with allowance for
stratification) will be used to construct the confidence
interval.
For the second supplementary analysis, the treatment
effect will be estimated using time (days) spent by partic-
ipants in acute hospitals in the 30 days post randomisa-
tion amongst only those participants who survived to 30
days post randomisation. The model for this supplemen-
tary analysis will include the same fixed effects described
in the main model for the primary outcome. The ana-
lysis model will be conditional on survival until 30 days
post randomisation; that is, the model will be fitted to a
subset of participants alive at this time. Treatment ef-
fects will be weighted means of the three centre-specific
treatment effects with weights proportional to the num-
ber of people randomised at each centre. As a check on
the robustness of results to normality assumptions, non-
parametric bootstrap methodology (bias corrected and
accelerated, 2000 replications, with allowance for stratifi-
cation) will be used to construct the confidence interval.
For patient-reported outcomes, an appreciable amount
of missing data is expected. This may be for a number of
reasons, such as participants being out of contact, being
too ill to complete questionnaires, or due to death. Two
levels of data missingness are anticipated: missing ques-
tionnaire items and missing outcome values. Missing
scale items will be addressed using individual mean im-
putation, provided that 20% or less of items are missing
for a given participant. Specifically, this involves calculat-
ing the within-participant mean of the non-missing
values for a particular questionnaire. This mean is then
used to impute the missing value(s), provided that the
number of missing items for that participant is small. It
has been shown that at low proportions of missing
items, the correlation between imputed and true values
is high, and there is no additional benefit of using more
sophisticated methods such as MI [23]. In addition,
missing outcome values are anticipated, some of which
will be due to the deaths of participants. It is considered
to be conceptually problematic to regard the outcomes
of those who die before the end of follow-up as properly
missing in a data modelling process. This is because it is
difficult to make any assumption or draw any inference
about a person’s health state if they are not alive. Mul-
tiple imputation by chained equations (MICE) provides
a method for valid estimation of treatment effects with-
out making assumptions about levels of outcomes for
those who have died. The method involves three steps.
In the first step, missing data are replaced by simulated
values drawn from the predicted distribution of missing
data conditional on observed data. This involves fitting a
model to the observed data, simulating a random draw
of the model parameters from their posterior distribu-
tion, and simulating random draws of the missing data
from this model. This is done a number of times,
thereby generating a number of imputed datasets. In the
second step, models are fitted to each imputed dataset
(providing estimated treatment effects). In the third step,
parameter estimates from multiply imputed datasets are
combined. Any variables and interaction terms used in
the analysis model (second step), together with any pre-
dictors of missingness, must be included in the imput-
ation (first) step. Imputation models will include any
variables in the main model (as listed in the previous
section), values of the variable being analysed at other
time points, and auxiliary variables. Auxiliary variables
are considered to be anything that is correlated with the
incomplete variable and is sometimes observed when the
incomplete variable is missing. These variables will in-
clude the following baseline demographic and clinical
variables that are considered to be possibly correlated
with incomplete outcomes:
 Usual place of residence
 Whether the participant was admitted from their
usual place of residence
 Where the patient was admitted from
 Relationship status
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 Employment status
 Whether the patient lives alone
 Deprivation score
 Rural/urban classification
The list of auxiliary variables will also include the pri-
mary outcome and secondary outcomes derived from
routine data/medical records (measured at baseline and
both post-randomisation time points). This implies that
baseline measurements of outcomes for those who die
will be allowed to contribute to the imputation process.
However, as mentioned above, the analysis will make no
assumptions about the levels of outcomes following
death. For this reason, imputed values for those partici-
pants who die before the end of follow-up will be dis-
carded before the analysis step. For each of secondary
outcomes 1–7, 100 multiply imputed datasets will be
generated. Imputation will be done separately for the
two randomised groups. For EQ-5D-5L, MICE will be
used to impute EQ-5D-5L values for alive participants,
and if the missingness is due to death, the EQ-5D-5L
values are set to be 0.
The main analysis of those outcomes collected from
routine data/medical records will use all available data
and assume that missing data are missing at random. In
the event that there is substantial missing data (> 10%
missing observations) or substantial imbalance in miss-
ing data between arms (difference in proportion of miss-
ing observations between trial arms > 10 percentage
points) for these outcomes, the use of MI with auxiliary
variables included in the imputation step will be consid-
ered. For the outcomes collected from routine data/med-
ical records, missing data due to death will be handled
in a number of ways, some of which have already been
described. For example, total length of index admission
(part of secondary outcome number 9) will be treated as
a time-to-event outcome with censoring for death. In
addition, discharge destination will be modelled only for
those participants who survived until discharge from
hospital. Total number of readmissions in the year fol-
lowing randomisation (part of secondary outcome num-
ber 9) will be modelled in two ways: using a count of
readmissions and using the number of readmissions
scaled by time alive (measured in years). Total time
(days) spent in hospital in the 1 year following random-
isation (part of secondary outcome number 9) will also
be modelled in two ways: using the total number of days
participants spent in hospital and using the total number
of days participants spent in hospital as a proportion of
time alive.
Pre-specified subgroup analysis
Pre-planned subgroup analyses are planned using the
randomisation stratification variables (hospital, sex, and
age groups) because it is anticipated that these are the
most likely effect modifiers. The models will be fitted for
the primary outcome using the same population as the
other effectiveness analyses (i.e., ITT population). The
models will include interactions terms between trial arm
and each of the stratification variables.
Supplementary/additional analyses and outcomes
A per-protocol analysis will be carried out for the pri-
mary outcome, as described earlier. This will be done by
fitting a model similar to that used for the primary out-
come. The difference will be that instead of using trial
arm as the exposure variable of interest, this variable will
be treatment receipt. The construction of this variable
was described earlier.
In addition, supplementary analyses will examine the
effect of data being collected from either patients or
proxies. Some secondary outcome data (Barthel Index of
Activities of Daily Living, EQ-5D-5L, PHQ-4, overall
quality of life, experience of hospital stay, view on length
of hospital stay) will be collected from proxies when par-
ticipants are unable to provide data. The following ana-
lyses will be performed:
 We will examine whether the occurrence of proxy
measurements differs materially by treatment arm.
 As a sensitivity analysis, we will fit an interaction
between proxy/non-proxy and treatment and allow
different variances for proxy/non-proxy.
The primary analysis will ignore whether data were
collected from patients or proxies, because the person
from whom data is collected may be influenced by
treatment.
Health economics and cost-effectiveness
The health economics analysis aims to assess the cost-
effectiveness of usual care plus PPM with usual care
alone. The analysis will take the perspective of the NHS.
Costs will be expressed in UK pound sterling (GBP) at
2019/2020 prices, and health outcomes will be expressed
in QALYs, in line with current UK guidance for eco-
nomic evaluations [24]. For the base case, cost-
effectiveness will be assessed over the 1-year trial period.
If there are found to be differences over this period
which may result in the cost-effectiveness results being
expected to differ over the longer term, extrapolation of
trial results will be conducted. Cost-effectiveness results
will be expressed in terms of incremental cost-
effectiveness ratios (ICERs) and incremental net health
benefits (NHBs) at thresholds of £13,000 [25], £20,000
and £30,000 per QALY [26]. If extrapolation is con-
ducted, costs and QALYs beyond 1 year will be
Magill et al. Trials          (2020) 21:373 Page 11 of 14
discounted at 3.5% per annum in line with UK recom-
mendations [26].
Resource use and costs
Resource use and costs in secondary care and interven-
tion costs will be estimated as part of the analysis. Sec-
ondary healthcare use in the 1 year post randomisation
will be recorded using routine data (hospital episode sta-
tistics; secondary outcome number 9). Liaison psychiatry
resource use (in both trial arms) will be estimated using
information from participants’ medical records. Staff re-
sources associated with PPM (in intervention arm only)
will be estimated on the basis of receipt of intervention.
Using NHS reference unit costs [27], Personal Social
Services Research Unit Cost of Health and Social Care
[28], costs of healthcare resource use, costs of interven-
tion, and total costs will be calculated for all patients in
the trial.
Health-related quality of life
QALYs will be the health outcome used in the cost-
effectiveness analysis. Health-related quality of life mea-
sured by the EQ-5D-5L (secondary outcome number 3)
is recorded at baseline and at 1 month and 3 months
post randomisation. Responses to EQ-5D-5L are trans-
formed into health-related quality of life weights using
two different methods (using van Hout et al.’s crosswalk
algorithm [18] and UK EQ-5D-3L value set [19] or the
new UK EQ-5D-5L value set [20]). Consistent with the
main analysis, the base case analysis will pool the EQ-
5D-5L assessed by patients themselves and proxies to-
gether. Other approaches to handling the patient- and
proxy-ratedEQ-5D-5L will be explored in a sensitivity
analysis. Patients will be assumed to experience constant
health-related quality of life from 3months onwards
until death or 1 year. Death within the 1-yearfollow-up
duration is informed by UK Office for National Statistics
mortality data (secondary outcome number 10). The
health-related quality of life weights and survival data
will be combined to estimate QALYs over the 1-year
period, based on the area under the curve method and
linear interpolation between time points [29], for all
patients.
Missing data
Where costs and EQ-5D scores are missing, MI will be
performed to replace each missing observation with a
set of imputed values following the method recom-
mended by Faria et al. for the imputation of economic
data [22]. Predictive mean matching will be used to en-
sure that imputed values are in the appropriate range
(e.g., no negative costs or EQ-5D scores greater than 1).
We will use MICE, and Rubin’s rules [30] will be
implemented for the subsequent analysis of multiple
datasets. All analyses will be conducted using Stata
software.
Analysis
In the within-trial analysis, costs and QALYs will be cal-
culated per patient and then analysed using both gener-
alised linear models and seemingly unrelated regression
models controlling for covariates to estimate the
incremental mean costs and QALYs of adding PPM to
usual care [31]. Covariates considered will be the same
as for the main statistical analysis, including the centre
(Cambridge, Exeter, or Oxford) by treatment interaction
terms and baseline health-related quality of life weight
for QALYs [32]. ICERs and incremental NHBs will be
calculated at thresholds of £13,000, £20,000 and £30,000
per QALY. The probability of usual care plus PPM com-
pared with usual care being cost-effective at different
cost-effectiveness thresholds will be calculated [33, 34]
and represented visually as a cost-effectiveness accept-
ability curve [35, 36]. Analyses will also be performed for
the pre-defined subgroups. A subgroup analysis will be
conducted for three centres to explore the centre-
specificcost-effectiveness.
If differences in costs or outcomes between usual care
plus PPM compared with usual care alone are found
over the trial period, which would be expected to differ
over the longer term, extrapolation of the trial results
will be conducted. A decision analytic model will be de-
veloped to capture the costs and QALYs over an appro-
priate time horizon (the time over which costs and
QALYs could be expected to differ between the manage-
ment strategies, which may be lifetime) [29, 37]. The
model structure will be developed with clinical input
and will synthesise data from the trial with other exter-
nal sources to estimate cost-effectiveness. Uncertainty in
the parameters in the model will be reflected using prob-
ability distributions, with the resulting overall decision
uncertainty presented using cost-effectiveness accept-
ability curves [34].
Specification of statistical packages
All analyses will be performed using Stata software.
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